Increase Cardiovascular Event in Patient with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention

Hayla Iqda Millisani, Indra Prasetya, Mohammad Saifur Rohman, Budi Satrijo

Abstract


Diabetes mellitus (DM) associated with increase major risk factors of cardiovascular disease, such as peripheral arteriopathy, ischemic heart disease, or cerebrovascular accident. The Framingham study showed that patient with DM considerably increase coronary artery disease (CAD), particularly in old patient and women. Prevalence of DM is rising and cardiovascular mortality associated with DM is the main problem in the world. Additionally, there is a higher death rate among DM patients following a myocardial infarction with complications, such as stent thrombosis, instent restenosis, and no reflow phenomenon can worse overall long term prognosis with CAD. This review c onsiders the mechanism for diabetes mellitus in CAD patient, expecially patient with DM can increase risk of major complication in patient CAD undergoing percutaneous coronary intervention (PCI).


Keywords


Diabetes Mellitus, Coronary Artery Disease, Percutaneous Coronary Intervention

Full Text:

PDF

References


Aronson D, Edelman ER. Coronary artery disease and diabetes mellitus. Cardiol Clin. 2014;32(3):439-455. doi:10.1016/j.ccl.2014.04.001

Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: Cardiovascular disease in diabetes mellitus. Circulation. 2016;133(24):2459-2502. doi:10.1161/CIRCULATIONAHA.116.022194

Flaherty JD, Davidson CJ. Diabetes and Coronary Revascularization. Vol 293.; 2005. www.jama.comwww.jama.com

Zamora A. Prognosis of Diabetic Patients with Coronary Heart Disease. Rev Esp Cardiol . Published online 2002:751-762.

Diabetology C, Aronson D, Rayfield EJ. Cardiovascular Diabetology How Hyperglycemia Promotes Atherosclerosis: Molecular Mechanisms.; 2002. http://www.cardiab.com/content/1/1/1

Li Y, Li XW, Zhang YH, et al. Prognostic significance of the hemoglobin A1c level in non-diabetic patients undergoing percutaneous coronary intervention: A meta-analysis. Chin Med J (Engl). 2020;133(18):2229-2235. doi:10.1097/CM9.0000000000001029

Kassaian SE, Goodarzynejad H, Boroumand MA, et al. Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting. Cardiovasc Diabetol. 2012;11. doi:10.1186/1475-2840-11-82

Pechlivani N, Ajjan RA. Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets. Front Cardiovasc Med. 2018;5. doi:10.3389/fcvm.2018.00001

Khalfallah M, Maria DA, Allaithy A. Impact of Stress Hyperglycemia on No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Glob Heart. 2022;17(1). doi:10.5334/GH.1111

Nusca A, Piccirillo F, Bernardini F, et al. Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data. Int J Mol Sci. 2022;23(13). doi:10.3390/ijms23137261

Kruger D. Neo-intimal hyperplasia, diabetes and endovascular injury. Cardiovasc J Afr. 2012;23(9):507-511. doi:10.5830/CVJA-2012-019

Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol. 1998;32(7):1866-1873. doi:10.1016/S0735-1097(98)00467-7

Indolfi C, Torella D, Cavuto L, et al. Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats. Circulation. 2001;103(24):2980-2986. doi:10.1161/01.CIR.103.24.2980

Wilson S, Mone P, Kansakar U, et al. Diabetes and restenosis. Cardiovasc Diabetol. 2022;21(1). doi:10.1186/s12933-022-01460-5

Yang CD, Shen Y, Lu L, et al. Visit-to-visit HbA1cvariability is associated with in-stent restenosis in patients with type 2 diabetes after percutaneous coronary intervention. Cardiovasc Diabetol. 2020;19(1). doi:10.1186/s12933-020-01111-7

Bittl JA. Percutaneous Coronary Interventions in the Diabetic Patient. Circ Cardiovasc Interv. 2015;8(4). doi:10.1161/CIRCINTERVENTIONS.114.001944

Endokrinologi Indonesia PEDOMAN PENGELOLAAN DAN PENCEGAHAN DIABETES MELITUS TIPE P. PEDOMAN PENGELOLAAN DAN PENCEGAHAN DIABETES MELITUS TIPE 2 DEWASA DI INDONESIA-2021 PERKENI i Penerbit PB. PERKENI.

Leon BM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015;6(13):1246. doi:10.4239/wjd.v6.i13.1246

Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. Published online August 25, 2023. doi:10.1093/eurheartj/ehad192

Capodanno D, Angiolillo DJ. Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients with Coronary Artery Disease and Diabetes Mellitus. Circulation. 2020;142(22):2172-2188. doi:10.1161/CIRCULATIONAHA.120.045465

Schubert M, Hansen S, Leefmann J, Guan K. Repurposing Antidiabetic Drugs for Cardiovascular Disease. Front Physiol. 2020;11. doi:10.3389/fphys.2020.568632




DOI: https://doi.org/10.21776/ub/hsj.2024.005.03.5

Refbacks

  • There are currently no refbacks.


Copyright (c) 2024 Hayla Iqda Millisani, Indra Prasetya

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.